Shattering Barriers: Sandoz Unleashes Affordable Hope for Millions Battling Bone Disease!
- Sandoz launches WYOST® & Jubbonti®, the first and only FDA-approved interchangeable denosumab biosimilars in the US.
- These revolutionary treatments offer new, affordable options for over 10 million patients with osteoporosis and cancer-related bone conditions.1
- This launch underscores Sandoz's leadership ambition in the US biosimilar market, building on its pioneering history.
A new dawn breaks for over 10 million Americans grappling with debilitating bone conditions and cancer-related skeletal events![1,4] Sandoz today unleashed WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) – not merely new treatments, but a revolution in care as the first and only FDA-approved interchangeable denosumab biosimilars. This landmark launch shatters previous barriers, offering potent, cost-effective alternatives to the reference medicines XGEVA® and Prolia®.[2,3]
For countless patients, this means vital, high-quality medication is finally within reach, easing the crushing financial burden that has often dictated access. As Keren Haruvi, President Sandoz North America, affirmed, these biosimilars help “improve access and affordability for US patients.” This sentiment is echoed by Claire Gill, CEO of the Bone Health and Osteoporosis Foundation, who celebrated that "patients now have access to more treatments they need and deserve.”
This audacious move is a cornerstone of Sandoz's growth strategy, reinforcing its position as a leader in biosimilars since introducing the first US biosimilar in 2015. Despite a competitive landscape and ongoing legal contexts surrounding biosimilar entries, Sandoz is decisively advancing its ambition to be the biosimilar leader, bringing critical relief to those affected by conditions that see half of women and a quarter of men over 50 suffer fractures.6
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.